The US Agency for Drug Control (FDA) has approved the first non-hormonal therapy to relieve hot flashes caused by menopause, a drug that contains a low dose of an antidepressant. paroxetine, which has been used in large doses for some time, and which is expected to be marketed in the United States from November.

The new drug has been tested in clinical trials conducted with about 1,175 women who suffered an average of ten daily hot flashes. After 12 weeks giving these women, either the drug or placebo, there was an average decrease of almost six episodes less in those who followed the therapy, compared to a reduction of four or five episodes per day in those who took placebo.

The new drug is presented as an alternative to hormone replacement therapy (HRT) if contraindicated

The drug is presented as an alternative to hormone replacement therapy (HRT) when contraindicated, or when the patient does not want to follow it for fear of its side effects, although the new therapy will also describe in its prospect the possible adverse effects that can occur , such as headache, nausea or fatigue, among others.

So far, women with discomfort due to menopause symptoms that are not treated with THS, resort to phytoestrogens or soy isoflavones, which act as natural estrogens, to reduce hot flashes. As for the substance that contains the new drug, paroxetine, it is a reuptake inhibitor serotonin, a neurotransmitter associated with the production of hot flashes, although its mechanism of action is not known in depth.

News flash about hot flashes: They can last longer than you think (November 2019).